Announcement on the Approval and Launch of Semaglutide Injection

Hybio Pharmaceutical Co., Ltd.·July 1, 2026·2 pages

✨ AI Summary

Shenzhen Hanmi Pharmaceutical Co., Ltd. announces the approval of its Semaglutide (H) Injection by the National Medical Products Administration. This marks the first domestically produced, fully chemically synthesized Semaglutide formulation approved under the Class 2.2 innovative drug category. The drug is indicated for type 2 diabetes patients, including those with cardiovascular disease, and has achieved commercialization in the US.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300199

Securities Abbreviation: Hanmi Pharmaceutical

Announcement No.: 2026-037

Shenzhen Hanmi Pharmaceutical Co., Ltd.

Announcement on the Approval and Launch of Semaglutide Injection

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Shenzhen Hanmi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Registration Certificate" for Semaglutide (H) Injection issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Approval Document

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.